Seizure-Control Effect of Levatiracetam on Juvenile Myoclonic Epilepsy and Other Epileptic Syndromes: Literature Review of Recent Studies
Iranian Journal of Child Neurology,
Vol. 9 No. 2 (2015),
1 April 2015
,
Page 1-8
https://doi.org/10.22037/ijcn.v9i2.6920
Abstract
How to Cite This Article: Hashemiaghdam A, Sharifi A, Miri M, Tafakhori A. Seizure-Control Effect of Levatiracetam on Juvenile Myoclonic Epilepsy and Other Epileptic Syndromes: Literature Review of Recent Studies. Iran J Child Neurol. Spring 2015;9(2):1-8.
Abstract
Objective
Various epileptic syndromes may present in adolescence and Juvenile Myoclonic Epilepsy (JME) is known to be the most common idiopathic generalized epileptic syndrome presenting itself with different types of seizure activity. The exact etiology of JME is still unknown, but hypoxia, storage disease, toxic-metabolic disorders, drug reactions, and neurodegenerative disorders have been revealed to cause disease manifestation. Previous research shows that JME includes 5–10% of all cases diagnosed with epilepsy. It is estimated to include 18% of idiopathic generalized epilepsies. Females are at higher risk of developing this condition. Levatiracetam (LEV) is an anti-epileptic drug that has become one of the most used drugs for the management of epileptic syndromes. It has less drug interactions, milder side effects, and broad-spectrum efficacy to make it an ideal drug to control seizures. Different mechanisms of actions have made LEV a novel anti-epileptic drug. This new medication can be used as a mono- or add-on therapy to previous anti-epileptic drugs. One of the clinically valuable pharmacological aspects of LEV is that it can be started at a high therapeutic dosage and is well tolerated. The median starting dosage varied according to patients underlying disease, age, and disease severity. We have also discussed the effect of LEV on other epileptic syndromes, which showed promising results in both adults and children. In childhood epilepsy, there is evidence proving that a higher rate of behavioral disturbances with neurological disorders can be improved by LEV therapy. Finally, our review showed the beneficial effects of LEV on seizure-control in different epileptic syndromes especially as a monotherapy.
- Juvenile myoclonic epilepsy
- Epileptic syndromes
- Levatiracetam
- Seizure-control
- Side effects
How to Cite
References
Montalenti E, Imperiale D, Rovera A, Bergamasco B, Benna P. Clinical features, EEG findings and diagnostic pitfalls in juvenile myoclonic epilepsy: a series of 63 patients. J Neurol Sci. 2001 Feb 15;184(1):65-70.
Vijai J, Cherian PJ, Stlaja PN, Anand A, Radhakrishnan K. Clinical characteristics of a South Indian cohort of juvenile myoclonic epilepsy probands. Seizure. 2003 Oct;12(7):490-6.
Shahnaz, Sher K, Abdul Sattar R. Clinical and EEG characteristics of Juvenile Myoclonic Epilepsy. Pak J Med Sci. 2014 Jan;30(1):12-5.
Genton P, Thomas P, Kasteleijn-Nolst Trenite DG, Medina MT, Salas-Puig J. Clinical aspects of juvenile myoclonic epilepsy. Epilepsy Behav. 2013 Jul;28 Suppl 1:S8-14.
Caviness JN, Brown P. Myoclonus: current concepts and recent advances. Lancet Neurol. 2004 Oct;3(10):598-607.
Thomas RH, Walsh J, Church C, Sills GJ, Marson AG, Baker GA, et al. A comprehensive neuropsychological description of cognition in drug-refractory juvenile myoclonic epilepsy. Epilepsy Behav. 2014 Jul;36:124-9.
Kwan P, Sander JW. The natural history of epilepsy: an epidemiological view. J Neurol Neurosurg Psychiatry. 2004 Oct;75(10):1376-81.
Harden C. Juvenile myoclonic epilepsy-what does the future look like? Epilepsy Curr. 2014 May;14(3):150-1.
Kotov AS. [Idiopathic generalized epilepsy in young women: choise of treatment strategy]. Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(6 Pt 2):45-8.
Karlov VA, Freidkova NV, Rusanova LV. [Complex therapy of idiopathic forms of epilepsy with small doses of valproates and levetiracetam]. Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(6 Pt 2):37-9.
Verrotti A, Cerminara C, Coppola G, Franzoni E, Parisi P, Iannetti P, et al. Levatiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents. Dev Med Child Neurol. 2008 Jan;50(1):29-32.
Letourneau K, Cieuta-Walti C, Deacon C. Epileptiform asymetries and treatment response in juvenile myoclonic epilepsy. Can J Neurol Sci. 2010 Nov;37(6):826-30.
Panayiotopoulos CP, Tahan R, Obeid T. Juvenile myoclonic epilepsy: factors of error involved in the diagnosis and treatment. Epilepsia. 1991 Sep-Oct;32(5):672-6.
Crespel A, Gelisse P, Reed RC, Ferlazzo E, Jerney J, Schmitz B, et al. Management of juvenile myoclonic epilepsy. Epilepsy Behav. 2013 Jul;28 Suppl 1:S81-6.
Mantoan L, Walker M. Treatment options in juvenile myoclonic epilepsy. Curr Treat Options Neurol. 2011
Aug;13(4):355-70.
Loughman A, Bowden SC, D’Souza W. Cognitive functioning in idiopathic generalised epilepsies: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2014 Mar 14.
Camfield CS, Striano P, Camfield PR. Epidemiology of juvenile myoclonic epilepsy. Epilepsy Behav. 2013 Jul;28 Suppl 1:S15-7.
Dailly E, Bouquie R, Bentue-Ferrer D. [Therapeutic drug monitoring of levetiracetam]. Therapie. 2010 Jan-
Feb;65(1):67-70.
Lyseng-Williamson KA. Spotlight on levetiracetam in epilepsy. CNS Drugs. 2011 Oct 1;25(10):901-5.
Deshpande LS, Delorenzo RJ. Mechanisms of Levatiracetam in the Control of Status Epilepticus and Epilepsy. Front Neurol. 2014;5:11.
Aneja S, Sharma S. Newer anti-epileptic drugs. Indian Pediatr. 2013 Nov 8;50(11):1033-40.
Ramantani G, Ikonomidou C, Walter B, Rating D, Dinger J. Levatiracetam: safety and efficacy in neonatal seizures. Eur J Paediatr Neurol. 2011 Jan;15(1):1-7.
Lyseng-Williamson KA. Levatiracetam: a review of its use in epilepsy. Drugs. 2011 Mar 5;71(4):489-514.
Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther. 1998 Feb;284(2):474-9.
Gentile V, Brunetto D, Leo I, Bonetti S, Verrotti A, Franzoni E. Clinical and neuropsychological
considerations in a case of unrecognized myoclonic epileptic jerks dramatically controlled by levetiracetam. Neuropediatrics. 2010 Dec;41(6):270-2.
Tonekaboni SH, Ghazavi M, Karimzadeh P, Mahvelati F, Ghofrani M. Efficacy of levetiracetam in children with refractory epilepsy as an add-on trial. Epilepsy research. 2010 Aug;90(3):273-7.
Belcastro V, Costa C, Galletti F, Rossi A, Tambasco N, Striano P. Rapid effect of levetiracetam in a case of
juvenile myoclonic epilepsy. Epilepsy Behav. 2009 Jan;14(1):269-70.
Magaudda A, Gelisse P, Genton P. Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-
Lundborg disease: clinical observations. Epilepsia. 2004 Jun;45(6):678-81.
Kim JS, Lee JH, Ryu HW, Lim BC, Hwang H, Chae JH, et al. Effectiveness of Intravenous Levatiracetam as an Adjunctive Treatment in Pediatric Refractory Status Epilepticus. Pediatr Emerg Care. 2014 Jul 24.
Auvin S, Chhun S, Berquin P, Ponchel E, Delanoe C, Chiron C. Aggravation of absence seizure related to
levetiracetam. Eur J Paediatr Neurol. 2011 Nov;15(6):508-11.
Babtain FA. Levatiracetam may worsen myoclonus in patients with juvenile myoclonic epilepsy: case reports. Clin Neuropharmacol. 2012 Jul-Aug;35(4):201-2.
Lagae L, Buyse G, Ceulemans B. Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial. Seizure. 2005 Jan;14(1):66-71.
Glauser TA, Dulac O. Preliminary efficacy of levetiracetam in children. Epileptic Disord. 2003 May;5
Suppl 1:S45-50.
Halma E, de Louw AJ, Klinkenberg S, Aldenkamp AP, DM IJ, Majoie M. Behavioral side-effects of levetiracetam in children with epilepsy: A systematic review. Seizure. 2014 Jun 12.
Grosso S, Franzoni E, Coppola G, Iannetti P, Verrotti A, Cordelli DM, et al. Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy. Seizure. 2005 Jun;14(4):248-53.
Verrotti A, D’Adamo E, Parisi P, Chiarelli F, Curatolo P. Levatiracetam in childhood epilepsy. Paediatr Drugs. 2010 Jun;12(3):177-86.
Montouris G, Abou-Khalil B. The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent? Epilepsia. 2009 Sep;50 Suppl 8:16-20.
Cohen J. Levatiracetam monotherapy for primary generalised epilepsy. Seizure. 2003 Apr;12(3):150-3.
Kossoff EH, Bergey GK, Freeman JM, Vining EP. Levatiracetam psychosis in children with epilepsy.
Epilepsia. 2001 Dec;42(12):1611-3.
Stephen LJ, Kelly K, Parker P, Brodie MJ. Levatiracetam monotherapy--outcomes from an epilepsy clinic. Seizure. 2011 Sep;20(7):554-7.
- Abstract Viewed: 537 times